Samatasvir (IDX719) is a highly potent, selective inhibitor of HCV NS5A that effectively inhibits HCV genotype 1-5 replicons with EC50 of 2-24 pM.
Samatasvir also retains full activity in the presence of HIV and hepatitis B virus (HBV) antivirals.
Samatasvir demonstrates an overall additive effect when combined with IFN-α, ribavirin, representative HCV protease, and nonnucleoside polymerase inhibitors or the nucleotide prodrug IDX184.
